Myriad Genetics Newsroom

Myriad Genetics Analyst Ratings

BenzingaJun 27 09:01 ET

Myriad Genetics Analyst Ratings

BenzingaJun 3 09:12 ET

Myriad Genetics Analyst Ratings

BenzingaMay 13 08:57 ET

Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)

TipRanksMay 13 07:11 ET

Myriad Genetics Analyst Ratings

BenzingaMay 8 13:57 ET

Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35

BenzingaMay 8 13:56 ET

Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)

TipRanksMar 6 07:40 ET

Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty

TipRanksMar 1 01:03 ET

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

TipRanksFeb 28 07:32 ET

Myriad Genetics: A Sell Rating Amidst Profitability and Growth Concerns

TipRanksFeb 28 06:57 ET

Myriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious Outlook

TipRanksFeb 27 21:55 ET

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

TipRanksFeb 8 07:39 ET

Myriad Genetics Analyst Ratings

BenzingaJan 30 08:58 ET

Myriad Genetics Analyst Ratings

BenzingaJan 29 10:33 ET

BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating

MT NewswiresJan 29 10:32 ET

Myriad Genetics Analyst Ratings

BenzingaDec 21, 2023 05:33 ET

Myriad Genetics Analyst Ratings

BenzingaDec 19, 2023 11:07 ET

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

BenzingaDec 14, 2023 06:36 ET

Myriad Genetics Analyst Ratings

BenzingaDec 13, 2023 11:56 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Myriad Genetics (MYGN), Revolution Medicines (RVMD) and Demant (OtherWILLF)

TipRanksNov 8, 2023 07:22 ET